Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsGold Coast Adakveo Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentGold Coast Health PlanPolicy N/A

    Adakveo (crizanlizumab) Coverage Criteria

    Customize your policy alerts

    Sign up for all goldcoasthealthplan policy alerts

    Know when goldcoasthealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medicare Part B prior authorization and coverage for Adakveo in patients aged 16 years and older with sickle cell disease, including indication, documentation, hydroxyurea step therapy, coding, dose, and coverage duration requirements.

    Policy Summary
    PayerGold Coast Health Plan
    PolicyAdakveo (crizanlizumab) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateAug 21, 2025
    Last ReviewAug 21, 2025
    Next Review DateN/A
    Key ActionSubmit documentation confirming the FDA-approved indication, supporting medical records, and six months of hydroxyurea therapy or an intolerance or contraindication.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥16 yearsMinimum age
    6 monthsHydroxyurea trial
    2 yearsCoverage duration
    J0791HCPCS code

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    5 mg
    Billing unit

    Adakveo Coverage Criteria

    Initial Adakveo Coverage

    Covered when all of the following are met:

    Adakveo coverage criteria

    • Covered indication: The patient has sickle cell disease and is 16 years of age or older, and Adakveo is requested to reduce the frequency of vaso-occlusive crises.Age ≥16 years
    • Documentation: Medical records supporting the request are provided.
    • Hydroxyurea prerequisite

      • Prior hydroxyurea trial: The patient first tried hydroxyurea for six months.6 months
      • Exception to trial: The patient has an intolerance or contraindication to hydroxyurea.

    Coding and Eligibility Details

    Covered HCPCS CodesHCPCSCovered
    J0791Adakveo (crizanlizumab)
    Patient age
    Minimum patient age16 years of age and older
    Covered populationAdults and pediatric patients
    Covered conditionSickle cell disease
    Hydroxyurea trial
    Required trial durationSix months
    Medication to tryHydroxyurea
    ExceptionAn intolerance or contraindication to hydroxyurea

    Prior Authorization and Documentation

    Prior Authorization

    Part B Prior Authorization

    Prior authorization is required under the Medicare Part B clinical guideline. The request must document that Adakveo (crizanlizumab) is being used for the FDA-approved indication: to reduce the frequency of vaso-occlusive crises in adults and pediatric patients 16 years of age and older with sickle cell disease (SCD).

    Step Therapy

    Hydroxyurea Prerequisite

    Before Adakveo approval, the patient must first try hydroxyurea for six months, unless the prescriber documents hydroxyurea intolerance or a contraindication.

    • Six-month hydroxyurea trial required.
    • An intolerance or contraindication may qualify as an exception.

    Therapy Overview

    Adakveo (crizanlizumab) is a selectin blocker indicated to reduce the frequency of vaso-occlusive crises in adults and pediatric patients 16 years of age and older with sickle cell disease (SCD).

    Key Terms

    Sickle cell disease (SCD)
    ConditionSickle cell disease (SCD)
    DescriptionA hereditary blood disorder
    Coverage contextAdakveo is indicated to reduce the frequency of vaso-occlusive crises in patients with SCD
    Adakveo (crizanlizumab)
    DrugAdakveo (crizanlizumab)
    Drug classSelectin blocker
    Covered therapeutic roleReduce the frequency of vaso-occlusive crises in patients with sickle cell disease

    Initial Therapy

    Initial Therapy

    Initial therapy is covered when all of the following are met:

    Initial therapy requirements

    • Indication and age: The patient has sickle cell disease, is 16 years of age or older, and treatment is intended to reduce the frequency of vaso-occlusive crises.Age ≥16 years
    • Medical records supporting the request are provided.
    • Hydroxyurea requirement or exception

      • Hydroxyurea trial: The patient first tried hydroxyurea for six months.6 months

    Required Prior Therapy

    StepRequirementException
    1Try hydroxyurea for six months before Adakveo.The patient has an intolerance or contraindication to hydroxyurea.

    Dose and Quantity Parameters

    Adakveo (crizanlizumab)
    Billing unit5 mg per billing unit
    Dose basisAccording to FDA-approved labeling or within accepted standards of medical practice
    HCPCS codeJ0791
    Policy Summary
    PayerGold Coast Health Plan
    PolicyAdakveo (crizanlizumab) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateAug 21, 2025
    Last ReviewAug 21, 2025
    Next Review DateN/A
    Key ActionSubmit documentation confirming the FDA-approved indication, supporting medical records, and six months of hydroxyurea therapy or an intolerance or contraindication.
    SourceLink
    On This Page
    Adakveo Coverage CriteriaCoding and Eligibility DetailsPrior Authorization and DocumentationTherapy OverviewKey TermsInitial TherapyRequired Prior TherapyDose and Quantity Parameters
    Adakveo billing unit
    Billing unit5 mg
    HCPCS codeJ0791
    Product supplied100 mg/10 mL single-dose vial
    Documentation Required

    Supporting Medical Records

    Submit medical records supporting the Adakveo request, including documentation of the diagnosis, FDA-approved SCD indication, and applicable hydroxyurea trial or exception.

    • Medical records supporting the request must be provided.
    Denial Risk

    Failure to Meet Coverage Criteria

    Requests that do not meet the coverage criteria may be denied. Adakveo is covered under this guideline only for the FDA-approved sickle cell disease indication and required prerequisite therapy or documented exception.

    • Coverage is subject to the FDA-approved labeling and applicable clinical criteria.
    • Requests outside the FDA-approved indication are at risk for denial.
  1. Hydroxyurea exception: The patient has an intolerance or contraindication to hydroxyurea.